Rae S. M. Yeung

Rae S. M. Yeung

Auto-generated profile, based on publicly available information

Rae S. M. Yeung

The Hospital for Sick Children and the University of Toronto Toronto Ontario Canada

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2021 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
PDF file
LHLauren A. Henderson
Lauren A. Henderson
SCScott W. Canna
Scott W. Canna
KFKevin G. Friedman
Kevin G. Friedman
MGMark Gorelik
Mark Gorelik
SLSivia K. Lapidus
Sivia K. Lapidus
JMJay J. Mehta
Jay J. Mehta

23 July 2020 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
PDF file
LHLauren A. Henderson
Lauren A. Henderson
SCScott W. Canna
Scott W. Canna
KFKevin G. Friedman
Kevin G. Friedman
MGMark Gorelik
Mark Gorelik
SLSivia K. Lapidus
Sivia K. Lapidus
JMJay J. Mehta
Jay J. Mehta

13 November 2011 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
HCHong Kong–Shanghai Kawasaki Disease Genetics Consortium
Hong Kong–Shanghai Kawasaki Disease Genetics Consortium
CKChiea Chuen Khor
Chiea Chuen Khor
KCKorean Kawasaki Disease Genetics Consortium
Korean Kawasaki Disease Genetics Consortium
TCTaiwan Kawasaki Disease Genetics Consortium
Taiwan Kawasaki Disease Genetics Consortium
ICInternational Kawasaki Disease Genetics Consortium
International Kawasaki Disease Genetics Consortium
MHMartin Hibberd
Martin Hibberd

1 August 2002 in The Journal of Pediatrics
Verified
Journal Article
Closed access
AHAdam M. Huber
Adam M. Huber
PLPei-Yoong Lam
Pei-Yoong Lam
CDCatherine M. Duffy
Catherine M. Duffy
RYRae S.M. Yeung
Rae S.M. Yeung
MDMichael Ditchfield
Michael Ditchfield
RLRonald M. Laxer
Ronald M. Laxer

3 February 2022 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
LHLauren A. Henderson
Lauren A. Henderson
SCScott W. Canna
Scott W. Canna
KFKevin G. Friedman
Kevin G. Friedman
MGMark Gorelik
Mark Gorelik
SLSivia K. Lapidus
Sivia K. Lapidus
JMJay J. Mehta
Jay J. Mehta
Objective: To provide guidance on the management of Multisystem Inflammatory Syndrome in Children (MIS‐C), a condition characterized by fever, inflammation, and multiorgan dysfunction that manifests late in the course of SARS–CoV‐2 infection. Recommendations are also provided for children with hyperinflammation during COVID‐19, the acute, infectious phase of SARS–CoV‐2 infection.Methods: The Task Force is composed of 9 pediatric rheumatologists and 2 adult rheumatologists, 2 pediatric cardiologists, 2 pediatric infectious disease specialists, and 1 pediatric critical care physician. Preliminary statements addressing clinical questions related to MIS‐C and hyperinflammation in COVID‐19 were developed based on evidence reports. Consensus was built through a modified Delphi process that involved anonymous voting and webinar discussion. A 9‐point scale was used to determine the appropriateness of each statement (median scores of 1–3 for inappropriate, 4–6 for uncertain, and 7–9 for appropriate). Consensus was rated as low, moderate, or high based on dispersion of the votes. Approved guidance statements were those that were classified as appropriate with moderate or high levels of consensus, which were prespecified before voting.Results: The guidance was approved in June 2020 and updated in November 2020 and October 2021, and consists of 41 final guidance statements accompanied by flow diagrams depicting the diagnostic pathway for MIS‐C and recommendations for initial immunomodulatory treatment of MIS‐C.Conclusion: Our understanding of SARS–CoV‐2–related syndromes in the pediatric population continues to evolve. This guidance document reflects currently available evidence coupled with expert opinion, and will be revised as further evidence becomes available.

1 October 2015 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
JGJaime Guzman
Jaime Guzman
KOKiem Oen
Kiem Oen
LTLori B Tucker
Lori B Tucker
AHAdam M Huber
Adam M Huber
NSNatalie Shiff
Natalie Shiff
CCClaire St. Cyr
Claire St. Cyr
Objective To describe clinical outcomes of juvenile idiopathic arthritis (JIA) in a prospective inception cohort of children managed with contemporary treatments. Methods Children newly diagnosed with JIA at 16 Canadian paediatric rheumatology centres from 2005 to 2010 were included. Kaplan–Meier survival curves for each JIA category were used to estimate probability of ever attaining an active joint count of 0, inactive disease (no active joints, no extraarticular manifestations and a physician global assessment of disease activity <10 mm), disease remission (inactive disease >12 months after discontinuing treatment) and of receiving specific treatments. Results In a cohort of 1104 children, the probabilities of attaining an active joint count of 0 exceeded 78% within 2 years in all JIA categories. The probability of attaining inactive disease exceeded 70% within 2 years in all categories, except for RF-positive polyarthritis (48%). The probability of discontinuing treatment at least once was 67% within 5 years. The probability of attaining remission within 5 years was 46–57% across JIA categories except for polyarthritis (0% RF-positive, 14% RF-negative). Initial treatment included joint injections and non-steroidal anti-inflammatory drugs for oligoarthritis, disease-modifying antirheumatic drugs (DMARDs) for polyarthritis and systemic corticosteroids for systemic JIA. Conclusions Most children with JIA managed with contemporary treatments attain inactive disease within 2 years of diagnosis and many are able to discontinue treatment. The probability of attaining remission within 5 years of diagnosis is about 50%, except for children with polyarthritis.